Effectiveness of Chinese Herbal Medicine for Older Adults With Urinary Incontinence
Effectiveness of Chinese Herbal Medicine for Older Adults With Urinary Incontinence: A Randomized Double-Blind Placebo-Controlled Clinical Trial
This study aims to evaluate the effectiveness and safety of Chinese herbal medicine in improving urinary incontinence symptoms among older adults. Urinary incontinence is a common condition in aging populations that can significantly impact quality of life, yet existing treatments are often limited by side effects or insufficient efficacy.
The primary research question is whether a standardized Chinese herbal formula can reduce the frequency and severity of urinary incontinence compared to a placebo. We hypothesize that participants receiving the herbal intervention will demonstrate greater improvement in urinary symptoms and quality of life measures than those receiving placebo, without significant adverse effects.
To test this hypothesis, a randomized, double-blind, placebo-controlled clinical trial will be conducted. Eligible older adults will be randomly assigned to receive either the herbal treatment or a matched placebo over a defined study period. Outcomes will include validated measures of urinary incontinence severity, frequency of episodes, and patient-reported quality of life.
Potential benefits of this research include generating high-quality evidence on the effectiveness and safety of Chinese herbal medicine for urinary incontinence, which may inform clinical practice and expand treatment options for older adults. If effective, this intervention could offer a complementary or alternative approach with fewer side effects, contributing to improved symptom management and overall well-being in this population.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:John Yang, Dr.
- 电话号码:604-599-2286
- 邮箱:john.yang@kpu.ca
学习地点
-
-
British Columbia
-
Richmond、British Columbia、加拿大、V6X 3X7
- Student Traditional Chinese Medicine Clinic
-
-
参与标准
资格标准
适合学习的年龄
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Experience symptoms of urinary incontinence (including stress, urge, or mixed incontinence) as confirmed by clinical assessment or validated screening tools.
- Able to understand the study procedures and provide informed consent.
- Willing and able to comply with study requirements, including attending study visits, and completing questionnaires.
- Stable general medical condition that, in the opinion of the investigator, does not interfere with participation in the study.
- Not currently participating in another interventional clinical trial that could affect urinary incontinence outcomes.
Exclusion Criteria:
- Inability to provide informed consent due to severe cognitive impairment or dementia.
- Known allergy or hypersensitivity to any component of the Chinese herbal medicine formulation.
- Presence of severe, unstable, or uncontrolled medical conditions that may pose a safety risk or interfere with participation, as determined by the investigator.
- Active urinary tract infection at the time of screening (eligible for reconsideration after treatment if appropriate).
- Current use of treatments for urinary incontinence that cannot be safely maintained at a stable dose throughout the study period.
- Significant neurological or urological conditions that severely affect bladder function, unless stable and deemed appropriate by the investigator.
- Participation in another interventional clinical trial that could influence study outcomes or participant safety.
- Any other condition that, in the opinion of the investigator, would compromise participant safety, study adherence, or data integrity.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:控制组
安慰剂
|
安慰剂对照
|
|
实验性的:Chinese Herbal Intervention
Standardized Chinese herbal medicine
|
Chinese Herbal Medicine (CHM) supplement
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF).
大体时间:From enrollment to approximately week 4.
|
Primary outcomes will focus on the frequency and severity of urinary incontinence episodes, measured using validated questionnaires.
Min = 0 and Max = 6, with higher scores indicating more frequent/severe urinary incontinence.
|
From enrollment to approximately week 4.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Urinary Incontinence Quality of Life Questionnaire (I-QOL)
大体时间:From enrollment to approximately Week 4.
|
Secondary outcomes include quality of life, symptom distress, and any adverse events.
A mean score for each subscale is calculated (averaging the scores for the items in each subscale) as well as a total score for all 22 items (sum of all subscale scores).
The scores are then transformed to a 'Scale score' ranging from 0-100 points for ease of interpretation: Scale score = (sum of the items - lowest possible score)/possible raw score range X 100.
|
From enrollment to approximately Week 4.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- KPU REB # 2022-22
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.